Dianthus Therapeutics, Inc. $DNTH Shares Purchased by SummitTX Capital L.P.

SummitTX Capital L.P. boosted its position in shares of Dianthus Therapeutics, Inc. (NASDAQ:DNTH) by 13.8% in the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 100,044 shares of the company’s stock after acquiring an additional 12,118 shares during the quarter. SummitTX Capital L.P.’s holdings in Dianthus Therapeutics were worth $8,396,000 at the end of the most recent quarter.

Other institutional investors also recently bought and sold shares of the company. First Horizon Corp purchased a new stake in Dianthus Therapeutics during the first quarter worth about $32,000. Caitong International Asset Management Co. Ltd purchased a new position in shares of Dianthus Therapeutics in the fourth quarter valued at approximately $40,000. Raymond James Financial Inc. purchased a new position in shares of Dianthus Therapeutics in the second quarter valued at approximately $27,000. Russell Investments Group Ltd. acquired a new position in shares of Dianthus Therapeutics in the third quarter valued at approximately $64,000. Finally, ABS Direct Equity Fund LLC acquired a new position in shares of Dianthus Therapeutics in the first quarter valued at approximately $179,000. 47.53% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

DNTH has been the topic of several recent research reports. TD Cowen reaffirmed a “buy” rating on shares of Dianthus Therapeutics in a research note on Wednesday, June 10th. Wedbush boosted their price target on shares of Dianthus Therapeutics from $103.00 to $105.00 and gave the stock an “outperform” rating in a research note on Wednesday, May 6th. Raymond James Financial restated a “strong-buy” rating on shares of Dianthus Therapeutics in a research note on Wednesday, June 10th. Wolfe Research reaffirmed an “outperform” rating on shares of Dianthus Therapeutics in a research report on Wednesday, June 10th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Dianthus Therapeutics in a research note on Friday, July 17th. One analyst has rated the stock with a Strong Buy rating, twelve have issued a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $117.82.

Dianthus Therapeutics Stock Performance

Shares of NASDAQ DNTH opened at $103.87 on Monday. The firm has a market capitalization of $5.68 billion, a PE ratio of -25.15 and a beta of 1.20. Dianthus Therapeutics, Inc. has a fifty-two week low of $18.08 and a fifty-two week high of $107.99. The stock’s 50-day simple moving average is $90.72 and its 200-day simple moving average is $76.22.

Dianthus Therapeutics (NASDAQ:DNTH) last posted its earnings results on Tuesday, May 5th. The company reported ($0.85) EPS for the quarter, beating analysts’ consensus estimates of ($1.07) by $0.22. Dianthus Therapeutics had a negative net margin of 12,998.50% and a negative return on equity of 27.30%. The firm had revenue of $0.46 million for the quarter, compared to the consensus estimate of $0.40 million. On average, sell-side analysts forecast that Dianthus Therapeutics, Inc. will post -3.82 earnings per share for the current fiscal year.

Insider Activity

In other news, EVP Ryan Savitz sold 31,249 shares of the firm’s stock in a transaction that occurred on Thursday, July 9th. The shares were sold at an average price of $101.03, for a total transaction of $3,157,086.47. Following the transaction, the executive vice president directly owned 31,249 shares in the company, valued at approximately $3,157,086.47. This trade represents a 50.00% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, EVP Simrat Randhawa sold 26,530 shares of the firm’s stock in a transaction on Monday, June 1st. The stock was sold at an average price of $90.62, for a total transaction of $2,404,148.60. Following the transaction, the executive vice president directly owned 4,000 shares in the company, valued at $362,480. The trade was a 86.90% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last ninety days, insiders sold 87,779 shares of company stock valued at $7,985,235. 3.02% of the stock is currently owned by company insiders.

About Dianthus Therapeutics

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc was founded in 2019 and is headquartered in New York, New York.